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The authors reply: To the Editor: It is encouraging to learn that other groups are interested in performing the QRS scoring system and attempting to determine the correlation between QRS score and other aspects of their patients with acute myocardial infarcts. It is reassuring to learn that significant correlations have been obtained between QRS score and enzyme-estimated infarct size and predischarge exercise performance as well as with the variable we evaluated, left ventricular ejection fraction. Since any method for estimating infarct size has some limitations, it is important that several methods for estimating size be available for optimal evaluation of the effect of any therapeutic intervention aimed at limiting infarct size. Our group is currently completing a retrospective evaluation of the relationship between enzyme-estimated and QRS-estimated size of initial mvcardial infarcts. We are also in the process of determining the relationship between the quantity of initial ST-segment elevation and both the final QRS score and the incidence of serious complications in hospital. GALEN S. WAGNER, M.D. Duke University Medical Center Durham, North Carolina
Irreversible Coronary Occlusion and Ergonovine
To the Editor:
We read with great interest the report of irreversible coronary occlusion related to administration of ergonovine by Crevey and co-workers (Circulation 64: 853, 1981). The patient described had multivessel coronary artery disease and sustained a total occlusion of the right coronary artery after a small dose of ergonovine (0.05 mg). This occlusion could not be reversed by large quantities of sublingual nitroglycerin and an acute transmural myocardial infarction resulted. They suggested that the ergonovine caused irreversible spasm. Review of figure I in their article suggests an alternative explanation. This figure shows a large intraluminal filling defect extending distally from the severe proximal stenosis. This closely resembles the intracoronary thrombi described by Ganz farction. We have seen identical lesions in these syndromes and documented their thrombotic nature by lysis with streptokinase. 4 It is possible that coronary occlusion in this instance was related to thrombosis alone, or was superimposed on spasm, rather than to irreversible spasm. In addition to treating the patient with apparent irreversible spasm with intracoronary nitroglycerin, consideration could also be given to intracoronary streptokinase therapy. NELSON M. WOLF. M.D. STEVEN G. MEISTER, M.D.
Department of Medicine Medical College of Pennsylvania
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